Penny Stock Gritstone Bio Hires Advisor To Evaluate Options, Analyst Downgrades Stock As Data ‘Insufficient To Excite Many Investors’
1
0
On Monday, Gritstone Bio Inc. (NASDAQ:GRTS) revealed interim Phase 2 data from the ongoing Phase 2 study evaluating GRANITE, its individualized neoantigen-targeting immunotherapy, in frontline microsatellite-stable colorectal cancer (MSS-CRC).
The study is designed to evaluate the clinical benefit of maintenance therapy with GRANITE (GRT-C901/GRT-R902) in combination with immune checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone.
The company says the greatest benefit was observed in the 50% of patients with lower disease burden at study entry, as measured by circulating tumor DNA (ctDNA) at study baseline.
- In all treated populations, GRANITE vs. standard of care (SOC) control was associated with a 21% relative risk reduction of progression …
Full story available on Benzinga.com
Visited 1 times, 1 visit(s) today